Evidence map›Paper›PMID 39522995›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Localized Unresectable Thymic Carcinoma Treated with Induction Chemotherapy with Lenvatinib before Radiotherapy.

Shodai Fujimoto, Naoko Katsurada, Rie Sasaki, Takeaki Ishihara, Daisuke Hazama, Masatsugu Yamamoto, Motoko Tachihara

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shodai FujimotoDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan.
Naoko KatsuradaDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan.
Rie SasakiDivision of Radiation Oncology, Kobe University Graduate School of Medicine, Japan.
Takeaki IshiharaDivision of Radiation Oncology, Kobe University Graduate School of Medicine, Japan.
Daisuke HazamaDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan.
Masatsugu YamamotoDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan.
Motoko TachiharaDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thymic carcinoma is a rare malignancy with limited treatment options. Lenvatinib, a novel multitarget kinase inhibitor, has recently been used to treat advanced or metastatic thymic carcinoma that cannot be surgically removed. To date, there have been no reports of lenvatinib being used as induction chemotherapy prior to radiotherapy in cases of localized, unresectable thymic carcinoma. We herein report an 85-year-old Japanese woman with localized unresectable thymic carcinoma who was treated with lenvatinib as induction chemotherapy before undergoing radiotherapy. Our findings suggest that lenvatinib may be a viable option for induction chemotherapy in similar clinical scenarios.

Indexed as

Antineoplastic AgentsInduction ChemotherapyPhenylurea CompoundsQuinolinesThymomaThymus NeoplasmsAged, 80 and overFemaleHumansTreatment OutcomeAntineoplastic AgentslenvatinibPhenylurea CompoundsQuinolinesinduction chemotherapylenvatinibradiotherapythymic carcinoma

Identifiers

PMID39522995
PMCPMC12222901

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.